Andres Maldonado
Stock Analyst at HC Wainwright & Co.
(4.18)
# 502
Out of 5,030 analysts
86
Total ratings
49.41%
Success rate
16.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMAB I-Mab | Reiterates: Buy | $7 | $5.77 | +21.32% | 1 | Jul 9, 2025 | |
| IBRX ImmunityBio | Reiterates: Buy | $8 | $2.40 | +233.33% | 4 | Jun 4, 2025 | |
| AURA Aura Biosciences | Assumes: Buy | $22 | $5.67 | +288.01% | 1 | May 28, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Buy | $10 | $1.49 | +571.14% | 1 | May 15, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $50 → $40 | $19.32 | +107.04% | 2 | May 7, 2025 | |
| TCRX TScan Therapeutics | Maintains: Buy | $15 → $10 | $2.48 | +303.23% | 1 | May 7, 2025 | |
| ERAS Erasca | Reiterates: Buy | $6 | $2.42 | +147.93% | 10 | Apr 30, 2025 | |
| FHTX Foghorn Therapeutics | Reiterates: Buy | $13 | $3.99 | +225.81% | 1 | Apr 30, 2025 | |
| STRO Sutro Biopharma | Reiterates: Neutral | $2 | $1.01 | +98.02% | 1 | Apr 29, 2025 | |
| TARA Protara Therapeutics | Reiterates: Buy | $23 | $5.49 | +318.94% | 1 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $75 | $41.46 | +80.90% | 13 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $7.20 | +400.00% | 14 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $6 | $2.07 | +189.86% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $1.60 | +837.50% | 16 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $9.35 | +167.38% | 2 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $50 | $27.94 | +78.95% | 13 | Nov 26, 2024 |
I-Mab
Jul 9, 2025
Reiterates: Buy
Price Target: $7
Current: $5.77
Upside: +21.32%
ImmunityBio
Jun 4, 2025
Reiterates: Buy
Price Target: $8
Current: $2.40
Upside: +233.33%
Aura Biosciences
May 28, 2025
Assumes: Buy
Price Target: $22
Current: $5.67
Upside: +288.01%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Buy
Price Target: $10
Current: $1.49
Upside: +571.14%
Corbus Pharmaceuticals Holdings
May 7, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $19.32
Upside: +107.04%
TScan Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $2.48
Upside: +303.23%
Erasca
Apr 30, 2025
Reiterates: Buy
Price Target: $6
Current: $2.42
Upside: +147.93%
Foghorn Therapeutics
Apr 30, 2025
Reiterates: Buy
Price Target: $13
Current: $3.99
Upside: +225.81%
Sutro Biopharma
Apr 29, 2025
Reiterates: Neutral
Price Target: $2
Current: $1.01
Upside: +98.02%
Protara Therapeutics
Apr 28, 2025
Reiterates: Buy
Price Target: $23
Current: $5.49
Upside: +318.94%
Apr 28, 2025
Reiterates: Buy
Price Target: $75
Current: $41.46
Upside: +80.90%
Apr 3, 2025
Reiterates: Buy
Price Target: $36
Current: $7.20
Upside: +400.00%
Mar 26, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $2.07
Upside: +189.86%
Mar 12, 2025
Reiterates: Buy
Price Target: $15
Current: $1.60
Upside: +837.50%
Mar 11, 2025
Reiterates: Buy
Price Target: $25
Current: $9.35
Upside: +167.38%
Nov 26, 2024
Maintains: Buy
Price Target: $40 → $50
Current: $27.94
Upside: +78.95%